Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

TCID50 assay for virus treated with tea

MS Masaharu Shin-Ya
MN Maiko Nakashio
EO Eriko Ohgitani
AS Akiko Suganami
MK Masaya Kawamoto
MI Masaki Ichitani
MK Makoto Kobayashi
TT Takanobu Takihara
TI Tohru Inaba
YN Yoko Nukui
HK Hitoshi Kinugasa
HI Hiroyasu Ishikura
YT Yutaka Tamura
OM Osam Mazda
request Request a Protocol
ask Ask a question
Favorite

The “original tea beverage” was placed into 96-well-plates at 180 μL/well (N = 3). SARS-CoV-2 suspension was added to the plate at 105 TCID50/20 μL/well (vol:vol = 9:1). Thus, virus was treated with a final concentration of × 9/10 (90%) of the original tea beverage. After incubation for 10 s, the virus/tea mixtures were serially diluted tenfold with MS. Chilled on ice, 50 μL of each sample was added to the VeroE6/TMPRSS2 cells that had been seeded into 96-well-plates at 5 × 104/100 μL/well a day before (N = 4). Cells were incubated for 1 h, followed by replacement of the supernatant by fresh 100 μL MS (DMEM supplemented with 0.5% FBS). After culture for 3 days, cytopathic effect (CPE) (cell death caused by Omicron variants of SARS-CoV-2) was observed under a phase contrast microscope33.

Copyright and License information: The Author(s) ©2023
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A